글로벌 34장
💊 합성의약품
[FDA 483 실사 관찰 · FDA]Central Alabama Veterans Health Care System
Evidence BFDASignal High · T3💊 합성의약품483
| 발행일 | 2026-05-27 |
| 문서번호 | fda483-192438 |
| 제조소/업체 | Central Alabama Veterans Health Care System · FEI 1073935 |
| 시설 · 유형 | Producer of Sterile Drug Products · 483 |
| 실사일 | 04/16/2026 |
[FDA 483 실사 관찰 · FDA]Intas Pharmaceutical Limited
Evidence BFDASignal High · T3💊 합성의약품483
| 발행일 | 2026-05-26 |
| 문서번호 | fda483-192689 |
| 제조소/업체 | Intas Pharmaceutical Limited · FEI 3005890633 |
| 시설 · 유형 | Drug Product Manufacturer · 483 |
| 실사일 | 09/17/2025 |
[FDA 483 실사 관찰 · FDA]Dabur India Limited
Evidence BFDASignal High · T3💊 합성의약품483
| 발행일 | 2026-05-26 |
| 문서번호 | fda483-192690 |
| 제조소/업체 | Dabur India Limited · FEI 3001413302 |
| 시설 · 유형 | OTC Drug Manufacturer · 483 |
| 실사일 | 01/16/2026 |
▫️ 기타
[Warning Letter · FDA]Pharmathen International S.A.
Evidence BFDASignal High · T3▫️ 기타CGMP
| 발행일 | 2026-06-16 |
| 문서번호 | d1e41608f7ba |
| 업체/제조소 | Pharmathen International S.A. |
| 발행 부서/일자 | Center for Drug Evaluation and Research (CDER) · 05/27/2026 |
[FDA 483 실사 관찰 · FDA]BPI Labs, LLC
Evidence BFDASignal High · T3▫️ 기타483
| 발행일 | 2026-05-27 |
| 문서번호 | fda483-192439 |
| 제조소/업체 | BPI Labs, LLC · FEI 3015156709 |
| 시설 · 유형 | Outsourcing Facility · 483 |
| 실사일 | 04/17/2026 |
[FDA 483 실사 관찰 · FDA]Wells Pharma of Houston LLC
Evidence BFDASignal High · T3▫️ 기타483
| 발행일 | 2026-05-27 |
| 문서번호 | fda483-192443 |
| 제조소/업체 | Wells Pharma of Houston LLC · FEI 3016710931 |
| 시설 · 유형 | Outsourcing Facility · 483 |
| 실사일 | 04/13/2026 |
[규제 소식 · ECA]GDP Non-Compliance Report: Missed CAPA Timelines lead to Ref…
Evidence BECASignal Med · T2GMP News
| 발행일 | 2026-06-18 |
| 문서번호 | 4399b537ba30 |
| 발행기관 | ECA |
| 주제 | GDP Non-Compliance Report: Missed CAPA Timelines lead to Refusal of GDP Certific… |
[지침·안내서 · FDA]Agency Information Collection Activities; Submission for Off…
Evidence AFDASignal Med · T2Guidance
| 발행일 | 2026-06-18 |
| 문서번호 | 2026-12237 |
| 발행기관 | FDA |
| 주제 | Agency Information Collection Activities; Submission for Office of Management an… |
원문
The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.
[지침·안내서 · FDA]Agency Information Collection Activities; Submission for Off…
Evidence AFDASignal Med · T2Guidance
| 발행일 | 2026-06-18 |
| 문서번호 | 2026-12238 |
| 발행기관 | FDA |
| 주제 | Agency Information Collection Activities; Submission for Office of Management an… |
원문
The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.
[규제 소식 · ECA]FDA Warning Letter: Deficiencies in Incoming Component Testi…
Evidence BECASignal Med · T2GMP News
| 발행일 | 2026-06-17 |
| 문서번호 | bfa2307d43e9 |
| 발행기관 | ECA |
| 주제 | FDA Warning Letter: Deficiencies in Incoming Component Testing, Stability Progra… |
[FDA 483 실사 관찰 · FDA]BlendHouse Portland LLC
Evidence BFDASignal Med · T2▫️ 기타483
| 발행일 | 2026-06-11 |
| 문서번호 | fda483-192871 |
| 제조소/업체 | BlendHouse Portland LLC · FEI 3013670080 |
| 시설 · 유형 | Manufacturer · Establishment Inspection Report (EIR) |
| 실사일 | 01/23/2026 |
[FDA 483 실사 관찰 · FDA]BlendHouse Allerton LLC
Evidence BFDASignal Med · T2▫️ 기타483
| 발행일 | 2026-06-11 |
| 문서번호 | fda483-192916 |
| 제조소/업체 | BlendHouse Allerton LLC · FEI 1921383 |
| 시설 · 유형 | Manufacturer · Establishment Inspection Report (EIR) |
| 실사일 | 01/22/2026 |
[지침·안내서 · FDA]Epizyme, Inc.
Evidence AFDASignal Low · T1Guidance
| 발행일 | 2026-06-22 |
| 문서번호 | 2026-12367 |
| 발행기관 | FDA |
| 주제 | Epizyme, Inc. |
원문
The Food and Drug Administration (FDA or Agency) is withdrawing approval of new drug application (NDA) for TAZVERIK (tazemetostat) tablet, 200 milligrams (mg), held by Epizyme, Inc., an Ipsen Company (Epizyme), 1 Main St., Cambridge, MA 02142.
[지침·안내서 · FDA]Medical Devices; Immunology and Microbiology Devices; Classi…
Evidence AFDASignal Low · T1Guidance
| 발행일 | 2026-06-22 |
| 문서번호 | 2026-12443 |
| 발행기관 | FDA |
| 주제 | Medical Devices; Immunology and Microbiology Devices; Classification of the Simp… |
원문
The Food and Drug Administration (FDA) is classifying the simple in vitro diagnostic device for the detection of secreted proteins from Bacillus species (spp.) in human clinical samples into class II (special controls).
[지침·안내서 · FDA]Medical Devices; Gastroenterology-Urology Devices; Classific…
Evidence AFDASignal Low · T1Guidance
| 발행일 | 2026-06-22 |
| 문서번호 | 2026-12444 |
| 발행기관 | FDA |
| 주제 | Medical Devices; Gastroenterology-Urology Devices; Classification of the Endosco… |
원문
The Food and Drug Administration (FDA) is classifying the endoscopic light-projecting measuring device into class II (special controls).
[지침·안내서 · FDA]Medical Devices; Gastroenterology-Urology Devices; Classific…
Evidence AFDASignal Low · T1Guidance
| 발행일 | 2026-06-22 |
| 문서번호 | 2026-12445 |
| 발행기관 | FDA |
| 주제 | Medical Devices; Gastroenterology-Urology Devices; Classification of the Endosco… |
원문
The Food and Drug Administration (FDA) is classifying the endoscopic traction device into class II (special controls).
[규제 소식 · EMA]Meeting highlights from the Committee for Veterinary Medicin…
Evidence BEMASignal Low · T1GMP News
| 발행일 | 2026-06-19 |
| 문서번호 | a539f45fec9e |
| 발행기관 | EMA |
| 주제 | Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 1… |
[규제 소식 · ECA]Questions and Answers from the ECA Webinar "GDP Update 2026"…
Evidence BECASignal Low · T1GMP News
| 발행일 | 2026-06-18 |
| 문서번호 | 1c4f028e2881 |
| 발행기관 | ECA |
| 주제 | Questions and Answers from the ECA Webinar "GDP Update 2026" - Part 4 |
[규제 소식 · ECA]GDPA Participated as an Observer in the EMA GMDP-IWG Interes…
Evidence BECASignal Low · T1GMP News
| 발행일 | 2026-06-18 |
| 문서번호 | ce1e12b61e37 |
| 발행기관 | ECA |
| 주제 | GDPA Participated as an Observer in the EMA GMDP-IWG Interested Parties Meeting |
[지침·안내서 · FDA]Advisory Committee; Science Board to the Food and Drug Admin…
Evidence AFDASignal Low · T1Guidance
| 발행일 | 2026-06-18 |
| 문서번호 | 2026-12235 |
| 발행기관 | FDA |
| 주제 | Advisory Committee; Science Board to the Food and Drug Administration; Renewal |
원문
The Food and Drug Administration (FDA) is announcing the renewal of the Science Board to the Food and Drug Administration by the Commissioner of Food and Drugs (the Commissioner).
[지침·안내서 · FDA]SpecGx LLC; Withdrawal of Approval of Abbreviated New Drug A…
Evidence AFDASignal Low · T1Guidance
| 발행일 | 2026-06-18 |
| 문서번호 | 2026-12236 |
| 발행기관 | FDA |
| 주제 | SpecGx LLC; Withdrawal of Approval of Abbreviated New Drug Application for Methy… |
원문
The Food and Drug Administration (FDA or Agency) is withdrawing approval of abbreviated new drug application (ANDA) 202608 for Methylphenidate Hydrochloride (HCl) Extended-Release (ER) tablets, 27 milligrams (mg), 36 mg, and 54 mg, held by SpecGx LLC…
[지침·안내서 · FDA]Agency Information Collection Activities; Proposed Collectio…
Evidence AFDASignal Low · T1Guidance
| 발행일 | 2026-06-18 |
| 문서번호 | 2026-12239 |
| 발행기관 | FDA |
| 주제 | Agency Information Collection Activities; Proposed Collection; Comment Request;… |
원문
The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency.
[지침·안내서 · FDA]Authorization of Emergency Use for Two Animal Drugs for the…
Evidence AFDASignal Low · T1Guidance
| 발행일 | 2026-06-18 |
| 문서번호 | 2026-12245 |
| 발행기관 | FDA |
| 주제 | Authorization of Emergency Use for Two Animal Drugs for the Prevention and Treat… |
원문
The Food and Drug Administration (FDA or the Agency) is announcing the issuance of two Emergency Use Authorizations (EUA) (Authorization) under the Federal Food, Drug, and Cosmetic Act (FD&C Act) for new animal products.
[규제 소식 · ECA]European GDP Association Developments January through April…
Evidence BECASignal Low · T1GMP News
| 발행일 | 2026-06-17 |
| 문서번호 | 92613444e102 |
| 발행기관 | ECA |
| 주제 | European GDP Association Developments January through April 2026 |
[규제 소식 · ECA]FDA adopts updated ICH Q8/Q9/Q10 Questions & Answers (R5)
Evidence BECASignal Low · T1GMP News
| 발행일 | 2026-06-17 |
| 문서번호 | c1adef04914d |
| 발행기관 | ECA |
| 주제 | FDA adopts updated ICH Q8/Q9/Q10 Questions & Answers (R5) |
[규제 소식 · ECA]BioPhorum Publishes a Roadmap for QC Sample Test Execution
Evidence BECASignal Low · T1GMP News
| 발행일 | 2026-06-17 |
| 문서번호 | e170a70f927c |
| 발행기관 | ECA |
| 주제 | BioPhorum Publishes a Roadmap for QC Sample Test Execution |
[지침·안내서 · FDA]Medical Devices; Gastroenterology-Urology Devices; Classific…
Evidence AFDASignal Low · T1Guidance
| 발행일 | 2026-06-17 |
| 문서번호 | 2026-12165 |
| 발행기관 | FDA |
| 주제 | Medical Devices; Gastroenterology-Urology Devices; Classification of the Ingesti… |
원문
The Food and Drug Administration (FDA) is classifying the ingestible gastrointestinal blood detection capsule into class II (special controls).
[지침·안내서 · FDA]Medical Devices; Radiology Devices; Classification of the Ra…
Evidence AFDASignal Low · T1Guidance
| 발행일 | 2026-06-17 |
| 문서번호 | 2026-12166 |
| 발행기관 | FDA |
| 주제 | Medical Devices; Radiology Devices; Classification of the Radiological Machine L… |
원문
The Food and Drug Administration (FDA) is classifying the radiological machine learning-based quantitative imaging software with predetermined change control plan into class II (special controls).
[지침·안내서 · FDA]Andrew Jonathan Morgan: Final Debarment Order
Evidence AFDASignal Low · T1Guidance
| 발행일 | 2026-06-17 |
| 문서번호 | 2026-12167 |
| 발행기관 | FDA |
| 주제 | Andrew Jonathan Morgan: Final Debarment Order |
원문
The Food and Drug Administration (FDA or the Agency) is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) debarring Andrew Jonathan Morgan for a period of 5 years from importing or offering for import any drug into the United…
[Warning Letter · FDA]Roen Health, Inc. dba RoenRx
Evidence BFDASignal Low · T1CGMP
| 발행일 | 2026-06-16 |
| 문서번호 | 1c12afdcf673 |
| 업체/제조소 | Roen Health, Inc. dba RoenRx |
| 발행 부서/일자 | Center for Drug Evaluation and Research (CDER) · 06/08/2026 |
[Warning Letter · FDA]OrderlyMeds LLC dba OrderlyMeds
Evidence BFDASignal Low · T1CGMP
| 발행일 | 2026-06-16 |
| 문서번호 | 4a58d2e02eb1 |
| 업체/제조소 | OrderlyMeds LLC dba OrderlyMeds |
| 발행 부서/일자 | Center for Drug Evaluation and Research (CDER) · 06/08/2026 |
[Warning Letter · FDA]FITISH
Evidence BFDASignal Low · T1CGMP
| 발행일 | 2026-06-16 |
| 문서번호 | de8dbe142778 |
| 업체/제조소 | FITISH |
| 발행 부서/일자 | Center for Drug Evaluation and Research (CDER) · 06/08/2026 |
[Warning Letter · FDA]Joi and Blokes dba Joi + Blokes
Evidence BFDASignal Low · T1CGMP
| 발행일 | 2026-06-16 |
| 문서번호 | f28938fbb3d2 |
| 업체/제조소 | Joi and Blokes dba Joi + Blokes |
| 발행 부서/일자 | Center for Drug Evaluation and Research (CDER) · 06/08/2026 |
[규제 소식 · EMA]Questions and answers on the impact of Mutual Recognition Ag…
Evidence BEMASignal Low · T1GMP News
| 발행일 | 2026-06-11 |
| 문서번호 | 1bae7194b5bc |
| 발행기관 | EMA |
| 주제 | Questions and answers on the impact of Mutual Recognition Agreement (MRA) betwee… |
국내 1장
[행정처분 · MFDS]경방신약(주)
Evidence AMFDSSignal High · T3💊 합성의약품행정처분
| 발행일 | 2026-06-17 |
| 문서번호 | admin-2026004434 |
| 업체 | 경방신약(주) |
| 처분 | 해당품목 제조업무정지 1개월(2026. 7. 1. ~ 2026. 7. 31.): 쎄파렉신캡슐(은교산), 소폐탕엑스과립(소청룡탕) |
원문
①○ 의약품 제조업자는 의약품을 제조하면서 제조관리기준서, 제품표준서 등에 따라 정확히 제조하여야 하고, 작성된 기준서 및 지시서를 준수하여야 하나, ‘쎄파렉신캡슐(은교산)’, ‘소폐탕엑스과립(소청룡탕)’에 대하여 다음과 같이 기준서를 준수하지 않은 사실이 있음
- 제조관리기준서 「원료 칭량 관리」(문서번호 PMN032, 승인일자 2025.
Recall 1장
[Recall(HC) · Health Canada][HC] Lancora Tablets; Broken / partial tablets in blister pa…
Evidence AHealth CanadaSignal Med · T2💊 합성의약품Recall
| 발행일 | 2026-06-16 |
| 문서번호 | hc-82222 |
| 업체 | 원문 미기재 |
| 제품 | Lancora 5 mg tablet |
| Class | Type III |
AI 자동 생성 안내 · 본 자료는 1차 공식 자료를 바탕으로 AI가 자동 작성한 규제 정보 요약입니다.
사실 항목은 출처·원본을 병기해 추적 가능하나, 시사점·점검 항목은 AI 해석으로 공식 견해나 법적 자문이 아닙니다. 의사결정 전 반드시 원문을 확인하십시오.
This digest is AI-generated from primary sources; interpretations are not official or legal advice — verify against the original before acting.